Clover Biopharmaceuticals, Ltd. (HKG:2197)
1.930
+0.060 (3.21%)
At close: Mar 6, 2026
Clover Biopharmaceuticals Market Cap
Clover Biopharmaceuticals has a market cap or net worth of 2.51 billion as of March 6, 2026. Its market cap has increased by 688.35% in one year.
Market Cap
2.51B
Enterprise Value
2.09B
Revenue
56.73M
Ranking
n/a
PE Ratio
n/a
Stock Price
1.93
Market Cap Chart
Since November 5, 2021, Clover Biopharmaceuticals's market cap has decreased from 15.03B to 2.51B, a decrease of -83.33%. That is a compound annual growth rate of -33.86%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 2.51B | -17.51% |
| Dec 31, 2025 | 3.04B | 871.54% |
| Dec 31, 2024 | 312.59M | -61.08% |
| Dec 29, 2023 | 803.26M | -76.01% |
| Dec 30, 2022 | 3.35B | -78.71% |
| Dec 31, 2021 | 15.73B | 4.62% |
| Nov 5, 2021 | 15.03B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AIM Vaccine | 3.61B |
| Medtide | 3.20B |
| BioDlink International Company | 3.11B |
| SinoMab BioScience | 2.70B |
| Antengene Corporation | 2.66B |
| Jiangsu Recbio Technology | 2.65B |
| Frontage Holdings | 2.19B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.98B |